Allogeneic hematopoietic cell transplantation in chemotherapy-induced aplasia in children with high-risk acute myeloid leukemia or myelodysplasia.
Adolescent
Antineoplastic Combined Chemotherapy Protocols
/ adverse effects
Child
Child, Preschool
Cytarabine
/ administration & dosage
Female
Follow-Up Studies
Graft vs Host Disease
/ etiology
Hematopoietic Stem Cell Transplantation
/ methods
Humans
Leukemia, Myeloid, Acute
/ pathology
Male
Myelodysplastic Syndromes
/ pathology
Neoplasm Recurrence, Local
/ pathology
Prognosis
Red-Cell Aplasia, Pure
/ chemically induced
Retrospective Studies
Transplantation Conditioning
Transplantation, Homologous
Vidarabine
/ administration & dosage
acute myeloid leukemia
hematopoietic cell transplantation
myelodysplasia
pediatrics
Journal
Pediatric blood & cancer
ISSN: 1545-5017
Titre abrégé: Pediatr Blood Cancer
Pays: United States
ID NLM: 101186624
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
15
08
2018
revised:
06
09
2018
accepted:
13
09
2018
pubmed:
16
10
2018
medline:
23
10
2019
entrez:
16
10
2018
Statut:
ppublish
Résumé
Relapse remains the most common cause of treatment failure after hematopoietic cell transplantation for acute myeloid leukemia. Inability to achieve hematologic complete remission has been a barrier to transplant for patients with refractory disease. We describe six children with refractory myeloid disease undergoing transplant in chemotherapy-induced aplasia, as a strategy to facilitate curative therapy in refractory patients. Clofarabine- or high-dose cytarabine-based chemotherapy regimens were used to achieve marrow aplasia, followed by reduced-intensity conditioning and allogeneic transplant before hematologic recovery. Long-term disease control was achieved in five, with one transplant-related mortality, suggesting the feasibility of this approach.
Substances chimiques
Cytarabine
04079A1RDZ
Vidarabine
FA2DM6879K
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e27481Informations de copyright
© 2018 Wiley Periodicals, Inc.